Compare EEX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | GHRS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | EEX | GHRS |
|---|---|---|
| Price | $4.42 | $15.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.70 | ★ $40.33 |
| AVG Volume (30 Days) | 29.4K | ★ 165.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.88 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $7.98 |
| 52 Week High | $5.45 | $19.51 |
| Indicator | EEX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 50.81 |
| Support Level | $3.42 | $11.84 |
| Resistance Level | $4.96 | $16.22 |
| Average True Range (ATR) | 0.23 | 0.82 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 50.00 | 66.67 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.